TALOPH(SH:600222) Xin Lang Cai Jing·2025-11-13 07:16Core Viewpoint - TaiLong Pharmaceutical has experienced a significant stock price increase, with a 13.75% rise over the past four days, indicating strong market interest and potential investor confidence [1]. Group 1: Company Overview - TaiLong Pharmaceutical Co., Ltd. is located in Zhengzhou, Henan Province, and was established on August 31, 1998, with its listing date on November 5, 1999 [1]. - The company operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drug manufacturing, and pharmaceutical wholesale, alongside preclinical research services [1]. - The revenue composition of the company includes 70.59% from drug manufacturing, 14.71% from drug research services, 14.42% from drug material circulation, and 0.28% from other sources [1]. Group 2: Fund Holdings - FuGuo Fund's top holding is TaiLong Pharmaceutical, with the FuGuo CSI 2000 ETF (563200) holding 16,900 shares, representing 0.39% of the fund's net value [2]. - The fund has realized a floating profit of approximately 6,422 yuan today, with a total floating profit of 15,400 yuan during the four-day price increase [2]. - The FuGuo CSI 2000 ETF was established on September 28, 2023, with a current scale of 28.1262 million yuan and has achieved a year-to-date return of 41.07% [2]. Group 3: Fund Manager Information - The fund manager of FuGuo CSI 2000 ETF is Niu Zhidong, who has a tenure of 10 years and 188 days [3]. - The total asset size of the fund is 24.849 billion yuan, with the best return during the manager's tenure being 124.69% and the worst being -88.81% [3].